Avid Bioservices Inc (CDMO)

[BioBS2012]

The END is clearly stated below for the SUNRISE Trial

Further study details as provided by Peregrine Pharmaceuticals:

Primary Outcome Measures: •Overall Survival [ Time Frame: Approximately up to 36 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures: •Progression-free survival [ Time Frame: Approximately up to 36 months ] [ Designated as safety issue: No ]

•Overall Response Rate [ Time Frame: Approximately up to 36 months ] [ Designated as safety issue: No ]

•Safety [ Time Frame: Approximately up to 36 months ] [ Designated as safety issue: Yes ]
As measured by adverse event rates and laboratory evaluations

Estimated Enrollment: 582
Study Start Date: December 2013
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)

https://www.clinicaltrials.gov/ct2/show/NCT01999673?term=bavituximab&rank=3